Summary
This prediction ended on 22.05.17 with a price of €12.36. The BUY prediction by Joe130978 for Evotec SE saw massive gains of 106.47%. Joe130978 has a follow-up prediction for Evotec SE where he still thinks Evotec SE is a Buy. Joe130978 has 50% into this predictionEvotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Evotec SE | -3.233% | -3.233% | -64.953% | -84.701% |
iShares Core DAX® | -1.114% | 3.430% | 25.966% | 25.039% |
iShares Nasdaq 100 | 1.816% | 6.911% | 30.390% | 48.139% |
iShares Nikkei 225® | 2.113% | 5.501% | 23.404% | 11.979% |
iShares S&P 500 | 2.038% | 5.327% | 30.881% | 46.982% |
Comments by Joe130978 for this prediction
In the thread Evotec AG diskutieren
Evotec bleibt beste deutsche Biotechaktie
Meine letzte Kaufempfehlung wurde wegen Erreichung des Kursziels automatisch beendet. Am Ende standen Kursgewinne von +28%. Bei einem Rücksetzer unter 6,00 Euro kann man wieder einsammeln. Das neue Kursziel: 8 Euro.
Update (10.3.2017): Nachdem die 8 Euro heute dank Kaufempfehlung von Berenberg (Kursziel: 9,50 Euro) übersprungen wurden, erhöhe ich das Kursziel auf 10 Euro. Allerdings erwarte ich hier keinen Durchmarsch, sondern eigentlich noch einen Rücksetzer an die 8 Euro Marke inkl. Konsolidierung (Seitwärtsbewegung) ehe es weiter nach oben geht.